Accordingly, the internal ATP levels were restored after TXNIP knockdown in imatinib-treated CML cells, and decreased after TXNIP overexpression (Fig. 5S, T). This evidence concerns the gene TXNIP and chronic myelogenous leukemia, BCR-ABL1 positive.